HC Wainwright Reiterates “Buy” Rating for CalciMedica (NASDAQ:CALC)

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 price target on the stock.

CalciMedica Stock Down 4.0 %

Shares of CALC opened at $1.91 on Tuesday. CalciMedica has a 12-month low of $1.81 and a 12-month high of $6.27. The stock has a market cap of $25.75 million, a P/E ratio of -1.77 and a beta of 1.20. The business’s fifty day moving average is $2.36 and its 200 day moving average is $3.13.

CalciMedica (NASDAQ:CALC) last released its earnings results on Thursday, March 27th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.14. On average, analysts expect that CalciMedica will post -2.21 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Stonepine Capital Management LLC purchased a new position in CalciMedica during the 4th quarter valued at approximately $1,660,000. Alyeska Investment Group L.P. bought a new position in shares of CalciMedica during the 4th quarter valued at approximately $1,318,000. Deerfield Management Company L.P. Series C grew its holdings in shares of CalciMedica by 30.0% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 1,300,000 shares of the company’s stock valued at $4,602,000 after purchasing an additional 300,000 shares in the last quarter. Renaissance Technologies LLC bought a new stake in CalciMedica in the fourth quarter worth $153,000. Finally, Corient Private Wealth LLC purchased a new stake in CalciMedica during the fourth quarter valued at $135,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.